| Name | Value |
|---|---|
| Revenues | 363.3M |
| Cost of Revenue | 238.6M |
| Gross Profit | 124.7M |
| Operating Expense | 150.7M |
| Operating I/L | -26.1M |
| Other Income/Expense | 3.5M |
| Interest Income | 5.3M |
| Pretax | -22.6M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -23.3M |
Tandem Diabetes Care, Inc. is a medical device company specializing in products for insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes the t:slim X2 pump, disposable insulin cartridge, and infusion set. The company also offers t:slim X2 with Basal-IQ and control IQ technology, t:slim X2 with G5 Integration, and the Tandem Device Updater. Additionally, it provides t:connect, a web-based data management application, and Sugarmate, a mobile app for insulin users. Tandem has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories, driving its revenue through the sale of these medical devices and related technologies.